Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critically Ill Patients
Launched by FRESENIUS KABI · Oct 28, 2019
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥18 years and ≤95 years, male or female
- • 2. Hospitalised in a medical, surgical, or trauma ICU for at least five consecutive calendar days and either admitted to the ICU during the predefined screening month or admitted to the ICU maximally 4 days before start of the screening month
- • 3. BMI ≥18.5 kg/m2 and ≤45 kg/m2
- • 4. Written informed consent or requirements of local/national ethical committee
- Exclusion Criteria:
- • 1. Burn injury
- • 2. Pre-existing neuromuscular or psychiatric disorders that preclude proper assessment of functional status
- • 3. Severe hypoxic brain injury or severe neurological diagnosis (e.g. meningitis, encephalitis, brain trauma, spinal cord injury) at the time of ICU admission that precludes proper assessment of functional status
- • 4. Receiving home parenteral nutrition at the time of ICU admission (e.g. due to short bowel syndrome)
- • 5. Receiving home enteral nutrition (tube feeding) at the time of ICU admission
- • 6. Chronic invasive or chronic non-invasive ventilatory support before ICU admission
- • 7. Patients with a legal representative in place before ICU admission
- • 8. Admission to the ICU for palliative care
- • 9. Previous participation in this study (if the screening month is repeated and a patient is re-admitted to the ICU during the repeated screening month, only ICU data collected for that patient during the original screening month will be included)
- • 10. Concurrent enrolment in a nutrition-related interventional study at the time of screening
About Fresenius Kabi
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technology, with a strong focus on the areas of intravenous (IV) therapies, infusion devices, and clinical nutrition. With a commitment to enhancing patient care, Fresenius Kabi conducts innovative clinical trials to develop high-quality pharmaceuticals and medical devices that address unmet medical needs. The company leverages its extensive expertise in drug formulation and delivery systems to advance therapeutic solutions across various clinical indications, ensuring safety and efficacy in diverse patient populations. Through its robust research and development initiatives, Fresenius Kabi aims to contribute significantly to the healthcare landscape and improve outcomes for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valenciennes, , France
Milano, , Italy
Stuttgart, , Germany
Barcelona, , Spain
Marseille, , France
Vienna, , Austria
Brussels, , Belgium
Lleida, , Spain
Edegem, , Belgium
Suresnes, , France
Gent, , Belgium
Leipzig, , Germany
Brussels, , Belgium
Suresnes, , France
Charleroi, , Belgium
Białystok, , Poland
Valladolid, , Spain
Liverpool, , United Kingdom
Burgos, , Spain
Liverpool, , United Kingdom
Madrid, , Spain
Munich, , Germany
Clermont Ferrand, , France
Angers, , France
Bochum, , Germany
Veszprém, , Hungary
Prague, , Czechia
Palma De Mallorca, , Spain
Besançon, , France
Székesfehérvár, , Hungary
Vigo, , Spain
Nyíregyháza, , Hungary
ústí Nad Labem, , Czechia
Arlon, , Belgium
Brussels, , Belgium
Ottignies, , Belgium
Tournai, , Belgium
Brno, , Czechia
Brno, , Czechia
Brno, , Czechia
Hradec Králové, , Czechia
Hradec Králové, , Czechia
Hradec Králové, , Czechia
Olomouc, , Czechia
Pardubice, , Czechia
Plzen, , Czechia
Plzen, , Czechia
Prague, , Czechia
Brest, , France
Caen, , France
Chambray Lès Tours, , France
La Tronche, , France
Lyon, , France
Saint étienne, , France
Vandœuvre Lès Nancy, , France
Berlin, , Germany
Berlin, , Germany
Hannover, , Germany
Kiel, , Germany
Wetzlar, , Germany
Budapest, , Hungary
Budapest, , Hungary
Debrecen, , Hungary
Foggia, , Italy
Nocera Inferiore, , Italy
Ravenna, , Italy
Rimini, , Italy
Bydgoszcz, , Poland
Katowice, , Poland
Kraków, , Poland
Opole, , Poland
Poznań, , Poland
Girona, , Spain
Madrid, , Spain
Valencia, , Spain
Stockholm, , Sweden
London, , United Kingdom
Patients applied
Trial Officials
Michael Hiesmayr, Prof. MD
Principal Investigator
Medical University of Vienna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials